Risk factors for heart failure hospitalizations among patients with atrial fibrillation. by Eggimann, L. et al.
RESEARCH ARTICLE
Risk factors for heart failure hospitalizations
among patients with atrial fibrillation
Lucien Eggimann1,2, Steffen Blum1,2,3, Stefanie Aeschbacher1,2, Andreas Reusser1,2,
Peter Ammann4, Paul Erne5, Giorgio Moschovitis6, Marcello Di Valentino7, Dipen Shah8,
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Patients with atrial fibrillation (AF) have an increased risk for the development of heart failure
(HF). In this study, we aimed to detect predictors of HF hospitalizations in an unselected AF
population.
Methods
The Basel Atrial Fibrillation Cohort Study is an ongoing observational multicenter cohort
study in Switzerland. For this analysis, 1193 patients with documented AF underwent clini-
cal examination, venous blood sampling and resting 12-lead ECG at baseline. Question-
naires about lifestyle and medical history were obtained in person at baseline and during
yearly follow-up phone calls. HF hospitalizations were validated by two independent physi-
cians. Cox regression analyses were performed using a forward selection strategy.
Results
Overall, 29.8% of all patients were female and mean age was 69 ±12 years. Mean follow-up
time was 3.7 ±1.5 years. Hospitalization for HF occurred in 110 patients, corresponding to
an incidence of 2.5 events per 100 person years of follow-up. Independent predictors for HF
were body mass index (HR 1.40 [95%CI 1.17; 1.66], p = 0.0002), chronic kidney disease
(2.27 [1.49; 3.45], p = 0.0001), diabetes mellitus (2.13 [1.41; 3.24], p = 0.0004), QTc interval
(1.25 [1.04; 1.49], p = 0.02), brain natriuretic peptide (2.19 [1.73; 2.77], p<0.0001), diastolic
blood pressure (0.79 [0.65; 0.96], p = 0.02), history of pulmonary vein isolation or electrical
cardioversion (0.54 [0.36; 0.80], p = 0.003) and serum chloride (0.82 [0.70; 0.96], p = 0.02).







Citation: Eggimann L, Blum S, Aeschbacher S,
Reusser A, Ammann P, Erne P, et al. (2018) Risk
factors for heart failure hospitalizations among
patients with atrial fibrillation. PLoS ONE 13(2):
e0191736. https://doi.org/10.1371/journal.
pone.0191736
Editor: Claudio Passino, Ospedale del Cuore G
Pasquinucci Fondazione Toscana Gabriele
Monasterio di Massa, ITALY
Received: October 24, 2017
Accepted: January 10, 2018
Published: February 2, 2018
Copyright: © 2018 Eggimann et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The consent forms,
as approved by the local ethics committee
(Ethikkommission Nordwest- und Zentralschweiz),
do not allow the data to be made publicly available.
The participants signed a consent form, which
states that data is exclusively available for
professional research staff. Therefore, scientific
proposals must be approved by the principal
investigator (Dr. D. Conen) to assure the
restrictions from the consent form and the local
ethics committee. In case of any inquiries
Conclusions
In this unselected AF population, several traditional cardiovascular risk factors and arrhyth-
mia interventions predicted HF hospitalizations, providing potential opportunities for the
implementation of strategies to reduce HF among AF patients.
Introduction
Atrial Fibrillation (AF) is the most common cardiac arrhythmia [1] and its incidence is
expected to further increase with the ageing of the population [2]. Lifetime risk for AF develop-
ment is 1 in 4 among individuals aged 40 years or older [3], Patients with AF face an increased
risk of developing stroke, heart failure (HF), cognitive dysfunction and death [4–7].
Prior studies have highlighted that HF is an important comorbidity associated with AF, and
both entities frequently coexist [6]. AF occurs in more than half of individuals with HF and
HF occurs in more than one third of individuals with AF [8]. While many studies have tar-
geted the prevention of stroke in AF patients [9], little attention has been placed on the preven-
tion of HF, despite its high prevalence and its important impact on affected patients [6, 10–
12]. There is also an important economical impact, as HF predicts future hospitalizations in
AF patients [13].
Therefore, it is important to recognize risk factors for incident HF events among AF
patients, potentially providing opportunities for preventive measures. However, comprehen-
sive assessments on risk stratification for HF in patients with AF are scarce. To our knowledge
there has no study been assessing the role of biomarkers such as brain natriuretic peptide
(BNP) to predict HF in AF patients [11, 14–19]. Furthermore, prior studies enrolled either
patients without history of HF or did not differentiate between known HF and no history of
HF [11, 14–19].
Therefore, this study aimed to assess different predictors for HF hospitalizations including




The Basel Atrial Fibrillation Cohort Study (BEAT- AF) is an ongoing prospective, observa-
tional multicenter cohort study performed in 7 centers in Switzerland. Overall, 1553 patients
with documented AF were included between 2010 and 2014. The main inclusion criterion
for study participation was previously documented AF. Patients with exclusively short, tempo-
rary AF episodes (e.g. AF following cardiac surgery) were excluded. Patients suffering from
an acute disease were enrolled after they had recovered from their acute illness. Of 1553
patients enrolled in this study, 324 patients were excluded from this analysis because of miss-
ing laboratory values and 36 patients due to missing ECG-, medical history- or lifestyle data,
resulting in a total number of 1193 patients. A total of 86 (7.2%) patients were lost to follow-
up. The study protocol was approved by the local ethics committees (Ethikkommission Nord-
west- und Zentralschweiz) and informed written consent was obtained from every participat-
ing patient.
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Baseline assessments
All study patients were asked to complete a questionnaire about lifestyle, personal factors and
comorbidities. Smoking status was categorized in current smokers and non-current smokers
(past or never smokers). Exercise was graded in either doing any regular exercise or no regular
exercise. Daily alcohol intake was classified as no alcohol consumption, moderate alcohol
consumption (men > 0< 24 g/d, women > 0< 12 g/d) and high alcohol consumption
(men > 24 g/d, women >12 g/d) [20]. Current medication, medical history, comorbidities
and history of arrhythmia interventions (defined as previous pulmonary vein isolation or elec-
trical cardioversion) were recorded.
At baseline, all patients underwent clinical examination, resting 12- lead ECG recording
and venous blood sampling at the local study center. Standard blood and chemistry results
were obtained at the local study center. Height and weight were directly measured using stan-
dardized devices. Body mass index (BMI) was calculated as weight in kg divided by height in
meters squared. Blood pressure was measured twice in a resting position. Resting heart rate
was obtained from the resting ECG. A 12-lead ECG was obtained with a standard ECG device
in every center. QT interval was adjusted for mean heart rate (QTc) using the Bazett formula
[21]. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation [22]. Antiarrhythmic drug (AAD)
intake was defined as treatment with rhythm control medication. AF was classified according
to the guidelines of the European Society of Cardiology into paroxysmal AF (self-terminating,
usually within 48 hours), persistent AF (episodes lasting longer than 7 days or requiring termi-
nation by cardioversion) or permanent AF (AF is accepted by the patient and the physician
and no attempts to restore sinus rhythm are performed) [1].
Follow- up assessments
A yearly follow- up by mail and phone call was performed to update current AF type, smoking
status, exercise habits and detailed medical history. The main outcome measure for this analy-
sis was hospitalization for HF. Hospitalization for HF was defined as at least overnight admis-
sion to the hospital with clinical symptoms (e.g. leg swelling/leg edema, distension of neck
veins, positive hepato-jugular reflux, rales or 3rd heart sound) and signs of HF resulting from
an abnormality of cardiac structure or function. For this study we used all outcome data avail-
able until 7th of April 2017. All HF events were validated by two independent physicians in a
standardized procedure, using all available information. In case of discordance, a third physi-
cian was involved.
Statistical analysis
Baseline characteristics for all patients were stratified by presence of known HF at baseline.
Categorical variables were presented as counts (percentages) and compared using Chi-square
tests. Distribution of continuous variables was checked using skewness, kurtosis and visual
inspection of the histogram. Normally distributed continuous variables were presented as
mean ± standard deviation (SD) and compared using Student’s t-tests. Skewed variables were
presented as median (interquartile range) and compared using Wilcoxon rank sum tests. Per-
son-years of follow-up were calculated as the time between the date of study enrollment and
the first occurrence of hospitalization for HF, death, loss to follow-up or 7th of April 2017.
To identify predictors for HF hospitalizations, we constructed Cox regression models to
assess hazard ratios (HR) and 95% confidence intervals (95%CI) and to adjust for potential
confounders. In a first step, continuous variables were used as quartiles in order to check for
linearity of the association. If the shape of the association was linear, these variables were used
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in the continuous form. For continuous variables, HR were calculated per one SD increase.
We then used a forward selection process to obtain a set of independent predictors. A p-value
of 0.05 was used as cut-off to enter the model. Variables used for the forward selection were:
Sex, age, BMI, resting heart frequency, systolic blood pressure, diastolic blood pressure, QRS
interval, QTc interval, alcohol consumption (moderate and high alcohol consumption),
known history of HF at baseline as well as the laboratory parameters albumin, brain natriuretic
peptide (BNP), C-reactive protein, chloride, potassium, serum lactate dehydrogenase, sodium
and eGFR. History of stroke, AF type (paroxysmal/ non paroxysmal), diabetes mellitus, device
implantation, atrial flutter, chronic kidney disease, obstructive sleep apnea, cardiac valve sur-
gery, coronary artery disease (CAD), hypertension, exercise, smoking habits, beta blocker
intake, AAD intake, and history of arrhythmia intervention were included as time updated
variables in the Cox regression model.
Given the strong impact of a previous history of HF on future HF hospitalizations [23, 24],
we performed a sensitivity analysis among those patients without a history of HF (n = 951).
The proportional hazard assumption was checked by including a logarithm of time x predictor
variable into the models, and no violations were detected [25]. As a sensitivity analysis we
recalculated the main models using competing risk subdistribution hazard models as described
by Fine and Gray [26]. A two-sided p value <0.05 was considered to indicate statistical signifi-
cance. All statistical analyses were performed using SAS 9.4 (SAS Corporation, Cary, North
Carolina, USA).
Results
We included 1193 patients in this study, 951 (79.7%) of them without a previous history of HF
at baseline. Baseline characteristics stratified by history of HF at baseline are presented in
Table 1. Mean age of all patients was 69 ±12 years. Overall, 29.8% were females and mean BMI
was 27 ±4.6 kg/m2, both without significant difference in patients with and without HF at base-
line. Paroxysmal AF was present in 32.6% and 60.4% of the patients with and without HF
(p<0.0001). Individuals with HF at baseline had more often diabetes mellitus (p = 0.0008).
Median BNP levels were 243 (128; 458) ng/L and 109 (52; 209) ng/L for patients with and with-
out a baseline history of HF (p<0.0001).
Over a mean follow-up of 3.7±1.5 years, 110 patients were hospitalized for HF. The inci-
dence for HF hospitalizations was 2.5 events per 100 person years of follow-up. Multivariable
adjusted predictors for incident HF are presented in Table 2, and include BMI (HR 1.40 [95%
CI 1.17; 1.66], p = 0.0002), chronic kidney disease (2.27 [1.49; 3.45], p = 0.0001), diabetes melli-
tus (2.13 [1.41; 3.24], p = 0.0004), QTc interval (1.25 [1.04; 1.49], p = 0.018), BNP (2.19 [1.73;
2.77], p<0.0001), diastolic blood pressure (0.79 [0.65; 0.96], p = 0.016), history of arrhythmia
intervention (0.54 [0.36; 0.80], p = 0.003) and serum chloride (0.82 [0.70; 0.96], p = 0.015).
Among patients without known HF at baseline, mean follow-up was 3.9 (±1.4) years. Hos-
pitalization for HF occurred in 60 patients. The incidence rate was 1.6 per 100 person years of
follow-up. Multivariable adjusted predictors associated with HF hospitalizations were age (HR
1.51 [95%CI 1.002; 2.29], p = 0.049), BMI (1.46 [1.14; 1.87], p = 0.003), diabetes mellitus (2.72
[1.57; 4.71], p = 0.0004), history of valve surgery (3.10 [1.58; 6.10], p = 0.001), QTc interval on
the ECG (1.44 [1.14; 1.83], p = 0.002), BNP (1.92 [1.30; 2.83], p = 0.001) and history of arrhyth-
mia intervention (0.41 [0.23; 0.76], p = 0.004), as shown in Table 2.
Results of the sensitivity analyses are presented in S1 Table. By taking death as a competing
risk into account, diastolic blood pressure and QTc interval were no longer significant predic-
tors of HF hospitalizations in the whole population. The HR for all other predictors remained
similar compared to the main model.
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Discussion
In this prospective cohort study of patients with AF, several independent risk factors for HF
hospitalizations were identified. Higher BMI, elevated BNP, diabetes mellitus, chronic kidney
disease and longer QTc interval were associated with an increased risk of HF, whereas patients
with higher diastolic blood pressure, higher serum chloride and history of arrhythmia-related
interventions were significantly less likely to develop HF. Finally, most risk factors identified
in this study were similar whether patients had known HF at baseline or not. Thus, although
the absolute risk for HF development is higher among patients with known HF [16, 18], pre-
ventive strategies are probably the same.
Several of these predictors are established cardiovascular risk factors and amenable to pre-
vention, providing a great potential opportunity to reduce the HF burden among patients with
AF. Both obesity and type 2 diabetes mellitus have been firmly related to the occurrence of car-
diovascular events [27–29], and both were related to AF and HF incidence [29–32]. Moreover,
prior studies have shown that they were associated with incident HF in patients with AF [11,
15, 17], a finding that is confirmed by our results. On the other hand, some studies suggested
that a higher BMI is associated with a lower all-cause mortality among AF patients [33, 34].
Additionally, in a cohort of patients suffering from AF and HF together, overweight and
Table 1. Baseline characteristics.
All patients (n = 1193) Patients without known HF at baseline
(n = 951)
Patients with known HF at baseline
(n = 242)
p-value
Age (years) 68.9 (±11.7) 68.1 (±11.8) 72 (±10.5) <0.0001
Female sex 356 (29.8%) 290 (30.5%) 66 (27.3%) 0.33
BMI (kg/m2) 27 (±4.6) 26.9 (±4.4) 27.4 (±5.1) 0.15
SBP (mmHg) 134.9 (±18.8) 136.7 (±18.4) 127.8 (±19) <0.0001
DBP (mmHg) 78.4 (±12.3) 79.3 (± 11.9) 74.7 (±13.2) <0.0001
Heart frequency (bpm) 67 (58; 80) 66 (57; 79) 70 (60; 83) 0.003
Paroxysmal AF 653 (54.7%) 574 (60.4%) 79 (32.6%) <0.0001
Diabetes mellitus 171 (14.3%) 120 (12.6%) 51 (21.1%) 0.0008
Hypertension 825 (69.2%) 630 (66.3%) 195 (80.6%) <0.0001
History of stroke 155 (13%) 121 (12.7%) 34 (14.1%) 0.58
Obstructive sleep apnea 135 (11.3%) 96 (10.1%) 39 (16.1%) 0.008
CAD 247 (20.7%) 162 (17%) 85 (35.1%) <0.0001
History of valve surgery 91 (7.6%) 51 (5.4%) 40 (16.5%) <0.0001
Chronic kidney disease 193 (16.2%) 96 (10.1%) 97 (40.1%) <0.0001
History of arrhythmia
intervention
544 (45.6%) 423 (44.5%) 121 (50%) 0.12
Current smoker 107 (9%) 82 (8.6%) 25 (10.3%) 0.41
Regular exercise 636 (53.3%) 539 (56.7%) 97 (40.1%) <0.0001
Beta blocker intake 832 (69.7%) 636 (66.9%) 196 (81%) <0.0001
AAD intake 340 (28.5%) 266 (28%) 74 (30.6%) 0.42
QTc interval (ms) 438.1 (±43.6) 433.4 (± 42.5) 456.4 (±43.1) <0.0001
BNP (ng/L) 128 (58; 252) 109 (52; 209) 243 (128; 458) <0.0001
Chloride (mmol/l) 102.5 (±3.15) 102.8 (±3) 101.5 (±3.6) <0.0001
Data are presented as number (percentages) or mean (± standard deviation) or median (interquartile range), as appropriate. BMI = body mass index; SBP = systolic
blood pressure; DBP = diastolic blood pressure; CAD = coronary heart disease; AAD = antiarrhythmic drug; BNP = brain natriuretic peptide; History of arrhythmia
intervention = previous pulmonary vein ablation or/and electrical cardioversion. Heart frequency and BNP were log-transformed.
 P-values compare patients with and patients without known HF at baseline and are based on chi-square tests or t-tests/Wilcoxon rank sum tests, as appropriate.
https://doi.org/10.1371/journal.pone.0191736.t001
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obesity were also associated with a lower risk of all-cause mortality [35]. Whether these differ-
ential findings suggests different associations between BMI and outcomes or whether they are
at least in part due to residual confounding should be assessed in future studies.
A prolonged QTc interval has been associated with a higher rate of cardiovascular events
including HF and death in a population based cohort [36]. However, in patients with AF there
is only little information available about this association. The results of our study presenting
prolonged QTc interval as an independent predictor for HF should be further investigated.
QTc interval can be easily assessed in clinical daily routine and therefore, it may be a simple
tool for risk stratification.
BNP levels are of major importance for the management of patients with acute or chronic
HF [37, 38]. To our knowledge, there is no prospective study assessing the relationship
between BNP levels and incident HF in patients with AF. The findings of our study indicate
that BNP is a strong predictor of HF also in patients with AF, who usually have a higher bur-
den of comorbidities and higher BNP levels compared to the general population [39, 40]. As
BNP levels were also predictive of incident HF among patients without a history of HF, BNP
may help to identify AF patients at increased risk of HF in the future. Previous history of
known HF, which was associated with increased risk of recurring HF generally [23, 24] and in
AF patients [16, 18], was not a predictor for future HF hospitalizations in our study, which
might be a result of the correlation between BNP and previous history of HF.
Several studies showed the prognostic implications of renal function in patients with heart
failure [41] and the relationship between renal function and cardiovascular morbidity and
mortality [42]. Additionally, renal dysfunction was also reported to promote HF in patients
with AF [14, 17], which is in line with our results. Low serum chloride was a predictor for HF
in our study, similar to a previously published population based cohort [43] and among
Table 2. Predictors of hospitalization for heart failure (HF) in patients with and without known HF at baseline.
HR (95% CI) p-value
Predictor in patients with and without known HF at baseline n = 1193
BMI (kg/m2) 1.40 (1.17; 1.66) 0.0002
Diastolic blood pressure (mmHg) 0.79 (0.65; 0.96) 0.016
Chronic kidney disease 2.27 (1.49; 3.45) 0.0001
Diabetes mellitus 2.13 (1.41; 3.24) 0.0004
History of arrhythmia intervention 0.54 (0.36; 0.80) 0.003
QTc interval (ms) 1.25 (1.04; 1.49) 0.018
BNP (ng/L) 2.19 (1.73; 2.77) < 0.0001
Chloride (mmol/l) 0.82 (0.70; 0.96) 0.015
Predictor in patients without known HF at baseline n = 951
Age (years) 1.51 (1.002; 2.29) 0.049
BMI (kg/m2) 1.46 (1.14; 1.87) 0.003
Diabetes mellitus 2.72 (1.57; 4.71) 0.0004
History of valve surgery 3.10 (1.58; 6.10) 0.001
History of arrhythmia intervention 0.41 (0.23; 0.76) 0.004
QTc interval (ms) 1.44 (1.14; 1.83) 0.002
BNP (ng/L) 1.92 (1.30; 2.83) 0.001
Data are Hazard Ratios (HR) and 95% confidence intervals (95%CI). HR for continuous variables are per one
standard deviation increase. BMI = body mass index; BNP = brain natriuretic peptide; history of arrhythmia
intervention = previous pulmonary vein ablation or/and electrical cardioversion. BNP was log-transformed.
https://doi.org/10.1371/journal.pone.0191736.t002
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patients with hypertension [44]. Moreover, there are some prognostic data available in patients
with acute decompensated [45] and chronic heart failure [46].
Higher DBP was associated with a better outcome in the current study. Previous studies
showed that low DBP was an independent predictor of re-hospitalization for HF in a cohort of
patients with acute decompensated HF [47]. Another study also related low DBP to higher
mortality in patients with systolic HF [48]. Low DBP might impair coronary blood flow during
diastole, which might result in a decreased coronary perfusion that affects the myocardium
and promotes the development of HF. Additionally, with increasing aortic stiffness, diastolic
BP is decreasing and the prognosis for adverse outcomes is increasing. Finally, arrhythmia-
related interventions but not AAD intake was associated with a reduced risk of incident HF in
our study. Prior studies on rhythm versus rate control did not show an advantage of rhythm
control [49]. Whether the current findings are due to selection bias or whether more modern
rhythm control interventions such as pulmonary vein isolation do have a prognostic benefit is
a question of ongoing trials.
Several risk scores to predict HF among AF patients have been evaluated. Imai et al.
included age, heart rate, hypertension und history of HF in their score [18]. In Suzuki et al.,
HF, anemia, renal dysfunction, diabetes mellitus and the use of diuretics were included [17].
More studies are needed to assess whether these differences across studies are due to differ-
ences in the patient populations, ethnicity, methodology used or other factors.
The strengths of this study are the large unselected cohort of extensively phenotyped
patients who were followed-up for a relatively long period of time. Limitations which need to
be considered when interpreting the results of this study are the following: First, due to obser-
vational study design, we are not able to prove causality. Second, despite the liberal inclusion
criteria, there is always a possibility of selection bias, or residual confounding. Third, the
patient population consists mainly of white individuals and the generalizability of our results is
unclear. Moreover, echocardiographic data was not systematically available. These data would
have been useful to improve the characterization of the study population. Fourth, updating
covariates such as AF type on a yearly basis may have induced some imprecision in the variable
classification.
Conclusion
In this large cohort of patients with AF, we found several potentially modifiable predictors of
HF, providing potential opportunities for the implementation of preventive strategies. Risk
factors were similar whether patients had known HF at baseline or not. Future studies should
assess whether modifying these risk factors can decrease the risk for HF in AF patients.
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S1 Table. Predictors of hospitalization for heart failure (HF) in patients with and without
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Mondet, Michael Kühne, Christian Sticherling, David Conen.
Resources: Stefan Osswald, David Conen.
Supervision: Peter Ammann, Paul Erne, Giorgio Moschovitis, Marcello Di Valentino, Dipen
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